-
Hotgen Biotech’s SGC001 Receives NMPA Approval for Clinical Trials in Myocardial Infarction
•
Hotgen Biotech Co., Ltd (SHA: 688068), a biopharmaceutical company based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its monoclonal antibody (mAb), SGC001. This emergency use mAb is intended for the treatment of anterior ST segment elevation myocardial infarction…
-
Hotgen Biotech Receives FDA Approval to Begin Clinical Trials for Acute Myocardial Infarction Drug
•
Hotgen Biotech Co., Ltd (SHA: 688068), a biopharmaceutical company based in China, has announced that it has received clinical trial approval from the U.S. Food and Drug Administration (FDA) for its innovative drug candidate, SGC001. SGC001, a monoclonal antibody (mAb) co-developed with Capital Medical University, is intended for the emergency…
-
Hotgen Biotech Receives FDA Clearance to Initiate Clinical Trials for SGC001
•
Hotgen Biotech Co., Ltd (SHA: 688068), a biopharmaceutical company based in China, has announced that it has received clinical trial approval from the U.S. Food and Drug Administration (FDA) for its innovative drug candidate, SGC001. SGC001 is an investigational monoclonal antibody (mAb) co-developed with Capital Medical University, designed for the…
-
Hotgen Biotech Partners with Genoval Therapeutics for RNAi Drug Development
•
China’s Hotgen Biotech Co., Ltd (SHA: 688068) has announced a strategic partnership between its anti-aging focused controlling subsidiary and Genoval Therapeutics Co., Ltd, a Shanghai-based developer of RNAi therapeutics. The collaboration aims to advance the development of multiple pioneering small nucleic acid drugs targeting the liver and extrahepatic tissues, addressing…
